Tizanidine Tablet
Product Images NDC 71610-776

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 71610-776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 4 mg (71610 0776 30)

Bottle Label 4 mg (71610 0776 30)
Tizanidine USP 4 mg oral tablets packaging label showing a bottle containing 30 tablets. The label includes storage instructions, manufacturer information as Apotex Inc., Toronto, Ontario, and repackager Aphena Pharma Solutions - Tennessee, LLC, Tennessee. The label also displays a lot number, batch, and expiration date fields along with a barcode and NDC 71610-0776-30.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Figure-1.jpg (Figure 1)

Figure-1.jpg (Figure 1)
A line graph depicting mean tizanidine concentration (ng/mL) versus time (hours from dosing) for 4 mg tablets and capsules under fasted and fed conditions. The graph compares plasma concentrations over a 24-hour period post-dose for both dosage forms with and without food intake.*
FDA Label Image

Figure-2.jpg (Figure 2)

Figure-2.jpg (Figure 2)
A line graph showing the mean change in muscle tone from baseline over 6 hours post-dose measured by the Ashworth Scale with 95% confidence intervals. It compares muscle tone improvement for 16 mg tizanidine, 8 mg tizanidine, and placebo, showing greater improvement with higher doses.*
FDA Label Image

Figure-3.jpg (Figure 3)

Figure-3.jpg (Figure 3)
A line graph titled 'Seven Week Study—Mean Change in Muscle Tone 0.5 to 2.5 Hours After Dosing as Measured by the Ashworth Scale ± 95% Confidence Interval.' It compares the improvement in Ashworth Score for tizanidine (mean dose 28.8 mg) and placebo at three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (last observation). The vertical axis shows improvement scores ranging from 2 to -6, with negative scores indicating improvement in muscle tone. Data points include means with error bars representing 95% confidence intervals.*
FDA Label Image

Chemical-structure (Tizanidine Imtb 01)

Chemical-structure (Tizanidine Imtb 01)
Chemical structure diagram of tizanidine hydrochloride, showing its molecular framework including chlorine and nitrogen atoms as part of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.